Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791211 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25867 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6758767 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19894397 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16359955 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL24359130 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL14389708 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL767955 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4942099 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Hydrochloric Acid SCHEMBL29919822 | 0.99 | SLC28A1 (0.71) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8059 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139255-A1 | RNAi Agent Targeting PCSK9 and Use Thereof | SYNERK BIOTECH LTD (CN) | 2026-05-21 | — | — | US | claimed |
| WO-2026103936-A1 | CHEMICALLY MODIFIED CIRCULAR RNA MOLECULE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海元码智药生物技术有限公司 | 2026-05-21 | — | — | WO | claimed |
| US-20260139251-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260132406-A1 | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739343-A2 | CIRCULAR RNA VACCINES FOR SEASONAL FLU AND METHODS OF USES | Shanghai Circode Biomed Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260125673-A1 | ARTIFICIAL POLYNUCLEOTIDES FOR EXPRESSING PROTEINS | CERTEST BIOTEC S L (ES) | 2026-05-07 | — | — | US | claimed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| US-6706691-B1 | BIOAVAILABILITY OF COMPOSITIONS METABOLIZED BY THE GUT P450 ISOZYMES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-03-16 | — | — | US | claimed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | claimed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| US-6355785-B1 | ENZYME INHIBITORS | ARONEX PHARMACEUTICALS, INC. | 2002-03-12 | — | — | US | claimed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | claimed |
| US-6323185-B1 | OLIGONUCLEOTIDE HAVING SPECIFIED NUCLEOTIDE SEQUENCE, OPTIONALLY MODIFIED AT 3' TERMINUS OR 5' TERMINUS BY ATTACHMENT OF SUBSTITUENT MOIETY SELECTED FROM PROPYLAMINE, POLY-L-LYSINE, CHOLESTEROL, FATTY ACID CHAINS AND VITAMIN E | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-11-27 | — | — | US | claimed |
| EP-0978561-A1 | Antisense oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-09 | — | — | EP | claimed |